Rein Therapeutics
Update in progressRNTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Rein Therapeutics Inc. is a biopharmaceutical company developing medicines for unmet needs in orphan pulmonary and fibrotic diseases in the United States. Its lead candidate, LTI-03, is a peptide in Phase 2 for idiopathic pulmonary fibrosis. LTI-01, a proenzyme, has completed Phase 1b/2a in loculated pleural effusion. The pipeline includes cystic fibrosis programs and a caveolin-1 peptide for systemic fibrosis, plus LTI-05 in preclinical CF. Formerly Aileron Therapeutics; renamed 2007. Founded 2001; based in Austin, Texas.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. James Brian Windsor Ph.D.
- Founded2001
- Employees10
- Websitewww.reintx.com
Identifiers
- ISINUS00887A2042
- FIGIBBG002454KR1
- CUSIP00887A204
- CIK0001420565